These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 29717332)

  • 1. Clinical utility of FDG-PET in amyotrophic lateral sclerosis and Huntington's disease.
    Agosta F; Altomare D; Festari C; Orini S; Gandolfo F; Boccardi M; Arbizu J; Bouwman F; Drzezga A; Nestor P; Nobili F; Walker Z; Pagani M;
    Eur J Nucl Med Mol Imaging; 2018 Jul; 45(9):1546-1556. PubMed ID: 29717332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective Validation of 18F-FDG Brain PET Discriminant Analysis Methods in the Diagnosis of Amyotrophic Lateral Sclerosis.
    Van Weehaeghe D; Ceccarini J; Delva A; Robberecht W; Van Damme P; Van Laere K
    J Nucl Med; 2016 Aug; 57(8):1238-43. PubMed ID: 26940764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 18F-FDG-PET correlates of cognitive impairment in ALS.
    Canosa A; Pagani M; Cistaro A; Montuschi A; Iazzolino B; Fania P; Cammarosano S; Ilardi A; Moglia C; Calvo A; Chiò A
    Neurology; 2016 Jan; 86(1):44-9. PubMed ID: 26590270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional pattern of brain FDG-PET in amyotrophic lateral sclerosis.
    Pagani M; Chiò A; Valentini MC; Öberg J; Nobili F; Calvo A; Moglia C; Bertuzzo D; Morbelli S; De Carli F; Fania P; Cistaro A
    Neurology; 2014 Sep; 83(12):1067-74. PubMed ID: 25122207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain
    Nobili F; Arbizu J; Bouwman F; Drzezga A; Agosta F; Nestor P; Walker Z; Boccardi M;
    Eur J Neurol; 2018 Oct; 25(10):1201-1217. PubMed ID: 29932266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic utility of 18F-Fluorodeoxyglucose positron emission tomography (FDG-PET) in asymptomatic subjects at increased risk for Alzheimer's disease.
    Drzezga A; Altomare D; Festari C; Arbizu J; Orini S; Herholz K; Nestor P; Agosta F; Bouwman F; Nobili F; Walker Z; Frisoni GB; Boccardi M;
    Eur J Nucl Med Mol Imaging; 2018 Jul; 45(9):1487-1496. PubMed ID: 29756163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical relevance of single-subject brain metabolism patterns in amyotrophic lateral sclerosis mutation carriers.
    Tondo G; Mazzini L; Caminiti SP; Sarnelli MF; Corrado L; Matheoud R; D'Alfonso S; Cantello R; Sacchetti GM; Perani D; Comi C; De Marchi F
    Neuroimage Clin; 2022; 36():103222. PubMed ID: 36223668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic network abnormalities in early Huntington's disease: an [(18)F]FDG PET study.
    Feigin A; Leenders KL; Moeller JR; Missimer J; Kuenig G; Spetsieris P; Antonini A; Eidelberg D
    J Nucl Med; 2001 Nov; 42(11):1591-5. PubMed ID: 11696626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Striatal hypometabolism in premanifest and manifest Huntington's disease patients.
    López-Mora DA; Camacho V; Pérez-Pérez J; Martínez-Horta S; Fernández A; Sampedro F; Montes A; Lozano-Martínez GA; Gómez-Anson B; Kulisevsky J; Carrió I
    Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2183-2189. PubMed ID: 27349245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 18F-FDG PET/CT: an unexpected case of Huntington's disease.
    Michels S; Buchholz HG; Rosar F; Heinrich I; Hoffmann MA; Schweiger S; Tüscher O; Schreckenberger M
    BMC Neurol; 2019 May; 19(1):78. PubMed ID: 31043171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicenter validation of [
    D'hulst L; Van Weehaeghe D; Chiò A; Calvo A; Moglia C; Canosa A; Cistaro A; Willekens SM; De Vocht J; Van Damme P; Pagani M; Van Laere K
    Amyotroph Lateral Scler Frontotemporal Degener; 2018 Nov; 19(7-8):570-577. PubMed ID: 29862846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic spatial connectivity in amyotrophic lateral sclerosis as revealed by independent component analysis.
    Pagani M; Öberg J; De Carli F; Calvo A; Moglia C; Canosa A; Nobili F; Morbelli S; Fania P; Cistaro A; Chiò A
    Hum Brain Mapp; 2016 Mar; 37(3):942-53. PubMed ID: 26703938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined brain and spinal FDG PET allows differentiation between ALS and ALS mimics.
    Van Weehaeghe D; Devrome M; Schramm G; De Vocht J; Deckers W; Baete K; Van Damme P; Koole M; Van Laere K
    Eur J Nucl Med Mol Imaging; 2020 Oct; 47(11):2681-2690. PubMed ID: 32314027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amyloid- and FDG-PET imaging in amyotrophic lateral sclerosis.
    Matías-Guiu JA; Pytel V; Cabrera-Martín MN; Galán L; Valles-Salgado M; Guerrero A; Moreno-Ramos T; Matías-Guiu J; Carreras JL
    Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):2050-60. PubMed ID: 27262702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brain Stem Glucose Hypermetabolism in Amyotrophic Lateral Sclerosis/Frontotemporal Dementia and Shortened Survival: An
    Zanovello M; Sorarù G; Campi C; Anglani M; Spimpolo A; Berti S; Bussè C; Mozzetta S; Cagnin A; Cecchin D
    J Nucl Med; 2022 May; 63(5):777-784. PubMed ID: 34503963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Testing the diagnostic accuracy of [18F]FDG-PET in discriminating spinal- and bulbar-onset amyotrophic lateral sclerosis.
    Sala A; Iaccarino L; Fania P; Vanoli EG; Fallanca F; Pagnini C; Cerami C; Calvo A; Canosa A; Pagani M; Chiò A; Cistaro A; Perani D
    Eur J Nucl Med Mol Imaging; 2019 May; 46(5):1117-1131. PubMed ID: 30617963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDG μPET Fails to Detect a Disease-Specific Phenotype in Rats Transgenic for Huntington's Disease – A 15 Months Follow-up Study.
    Reilmann R; Lippross V; Hölzner E; Gigengack F; Bohlen S; Kugel H; Deppe M; Osada N; Lücke M; Riess O; Nguyen HP; Von Hörsten S; Schäfers K; Schäfers M; Jacobs AH; Hermann S
    J Huntingtons Dis; 2015; 4(1):37-47. PubMed ID: 26333256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Value of 18fluorodeoxyglucose-positron-emission tomography in amyotrophic lateral sclerosis: a prospective study.
    Van Laere K; Vanhee A; Verschueren J; De Coster L; Driesen A; Dupont P; Robberecht W; Van Damme P
    JAMA Neurol; 2014 May; 71(5):553-61. PubMed ID: 24615479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Positron emission tomography in amyotrophic lateral sclerosis: Towards targeting of molecular pathological hallmarks.
    Willekens SM; Van Weehaeghe D; Van Damme P; Van Laere K
    Eur J Nucl Med Mol Imaging; 2017 Mar; 44(3):533-547. PubMed ID: 27933416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brain hypermetabolism in amyotrophic lateral sclerosis: a FDG PET study in ALS of spinal and bulbar onset.
    Cistaro A; Valentini MC; Chiò A; Nobili F; Calvo A; Moglia C; Montuschi A; Morbelli S; Salmaso D; Fania P; Carrara G; Pagani M
    Eur J Nucl Med Mol Imaging; 2012 Feb; 39(2):251-9. PubMed ID: 22089661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.